For prediction of MACE in the whole population (n = 533 patients*) | The 4 high-risk clinical items | Initial positive troponin assay | Troponin rise |
---|---|---|---|
Sensitivity, % (95% CI) | 100.0 (54.1–100) | 83.3 (35.9–99.6) | 33.3 (4.3–77.7) |
Specificity, % (95% CI) | 76.6 (73.4–79.6) | 97.7 (96.1–98.8) | 99.2 (98.3–99.7) |
Predictive value, % (95% CI) | Â | Â | Â |
Positive | 4.3 (3.8–4.9) | 29.3 (17.5–44.6) | 24.9 (7.7–56.9) |
Negative | 100.0 (99.9–100.0) | 99.9 (99.2–99.9) | 99.5 (99.1–99.7) |
Likelihood ratio (95% CI) | Â | Â | Â |
Positive | 4.6 (4.1–5.2) | 36.6 (18.8–71.1) | 43.3 (10.8–172.7) |
Negative | 0 | 0.17 (0.03–1.02) | 0.7 (0.4–1.2) |
Accuracy, % (95% CI) | 76.9 (73.7–79.8) | 97.6 (95.9–98.7) | 98.7 (97.7–99.4) |
For prediction of MACE in high-risk population (= 153 patients*) | Initial positive troponin assay | Troponin rise |
---|---|---|
Sensitivity, % (95% CI) | 83.3 (35.9–99.6) | 33.3 (4.3–77.7) |
Specificity, % (95% CI) | 95.2 (90.4–98.1) | 97.2 (93.5–99.1) |
Predictive value, % (95% CI) | Â | Â |
Positive | 41.7 (24.2–61.5) | 28.5 (8.8–62.4) |
Negative | 99.3 (95.9–99.9) | 97.7 (96.1–98.7) |
Likelihood ratio (95%CI) | Â | Â |
Positive | 17.5 (7.8–39.2) | 11.8 (2.8–49.0) |
Negative | 0.2 (0.0–1.1) | 0.7 (0.4–1.2) |
Accuracy, % (95% CI) | 94.8 (90.0–97.7) | 95.1 (90.9–97.7) |